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may play an important pathogenic role through the production
of chimeric HBV-human transcripts. We aimed to screen the
transcriptome for HBV integrations in HCCs.
Methods: Transcriptome sequencing was performed on paired
HBV-associated HCCs and corresponding non-tumorous liver
tissues to identify viral-human chimeric sites. Validation was
further performed in an expanded cohort of human HCCs.
Results: Here we report the discovery of a novel pre-mRNA splic-
ing mechanism in generating HBV-human chimeric protein. This
mechanism was exemplified by the formation of a recurrent
HBV-cyclin A2 (CCNA2) chimeric transcript (A2S), as detected
in 12.5% (6 of 48) of HCC patients, but in none of the 22 non-
HCC HBV-associated cirrhotic liver samples examined. Upon the
integration of HBV into the intron of the CCNA2 gene, the
mammalian splicing machinery utilized the foreign splice sites
at 282 nt. and 458 nt. of the HBV genome to generate a pseudo-
exon, forming an in-frame chimeric fusion with CCNA2. The A2S
chimeric protein gained a non-degradable property and
promoted cell cycle progression, demonstrating its potential
oncogenic functions.
Conclusions: A pre-mRNA splicing mechanism is involved in the
formation of HBV-human chimeric proteins. This represents a
novel and possibly common mechanism underlying the forma-
tion of HBV-human chimeric transcripts from intronically
integrated HBV genome with functional impact.Journal of Hepatology 20
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Hepatocellular carcinoma (HCC) is a leading cancer worldwide
and specifically prevalent in China and Southeast Asia [1,2], due
to prevalent hepatitis B virus (HBV) infection. In most of the HCCs
developed in chronic HBV carriers, the viral DNA sequence is
clonally integrated into the host genome [3] and HBV integration
into human genome is a major causative factor for HBV-
associated HCC [4]. In some cases, insertion of the HBV promoter
sequences into the host chromosomal DNA leads to abnormal or
increased transcription of host sequences [5]. HBV integration
was also found to disrupt chromosomal stability with subsequent
chromosomal re-arrangements. It is also generally reported that
truncation or alteration of host genes by HBV insertions gener-
ates novel fusion proteins with altered oncogenic properties
[6,7]. Although HBV integration is shown to be involved in hepa-
tocarcinogenesis, the role of HBV integration in HCC development
has not been fully elucidated.
Recently, with the advances in next generation sequencing
technologies [8], the preferential integration sites and functional
impact of viral integration into the host genome can be studied in
a more global and extensive manner. For instance, Sung et al.,
using whole-genome sequencing, identified recurrent HBV inte-
grations at several cancer-related genes (such as TERT, MLL4
and ROCK1) in human HCC [9]. However, that study focused on
viral genomic integration sites only and the functional conse-
quences of genome disruption by viral insertion were minimally
addressed. As the functional impact of HBV integration can also
be mediated through transcriptional modification, a comprehen-
sive analysis of the HBV insertion sites focusing on the transcrip-
tome would allow identification of chimeric HBV-human
transcripts in HCC and their functional consequences.16 vol. 64 j 1256–1264
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In our present study, we aimed to identify novel HBV-human
chimeras and delineate the underlying mechanisms in generation
of chimeras with an unbiased, transcriptional level and single-
base resolution tool in human HCCs. With whole-transcriptome
sequencing performed on 16 pairs of HCCs and non-tumorous liv-
ers (NT-Ls), we identified a novel mechanism for the formation of
HBV-human chimeric transcripts from intronically integrated
HBV genome, which was further validated in an expanded cohort
of 32 pairs of HCCs and NT-Ls. This mechanism resulted in the
generation of a novel and recurrent HBV-cyclin A2 (CCNA2)
fusion transcript, A2S. CCNA2 is a cell cycle regulatory protein
and acts as a regulatory subunit of cyclin-dependent kinase
(CDKs). Here we uniquely demonstrated that A2S was produced
by a novel pre-mRNA splicing of the HBV genome, after HBV inte-
gration at the intron 2 of CCNA2 gene, to form a 177 bp in-frame
pseudo-exon. Upon the HBV pseudo-exon fusion, the destruction
box (D-box) of A2S protein was disrupted, resulting in a gain of
non-degradable property. Moreover, A2S retained an intact func-
tion in enhancing the cell cycle progression, hence demonstrating
its potential role in tumor development. Altogether, we identified
a novel pre-mRNA splicing mechanism resulting in a HBV-human
chimeric transcript from intronically integrated HBV genome
with functional impact.Materials and methods
Patient samples
Forty-eight pairs of human HCCs and their corresponding NT-L tissues from
patients with liver resection for HCC between 1991 and 2001 at Queen Mary
Hospital, Hong Kong were selected. All these 48 patients had positive serum hep-
atitis B surface antigen (HBsAg) status. The age of patients ranged from 24 to
71 years; 36 were male and 12 female. All specimens were snap-frozen in liquid
nitrogen and kept at 80 C. Frozen sections were cut from HCC and NT-L blocks
separately and stained for histological examination to ensure a homogenous cell
population of tissues. Use of human samples was approved by the institutional
review board of the University of Hong Kong/Hospital Authority Hong Kong West
Cluster (UW 09-185).
Transcriptome sequencing
Transcriptome sequencing of both HCC and corresponding NT-L tissue samples
was performed by Axeq (Seoul, Korea), using 100 bp pair-end sequencing on
the HiSeq 2000 platform. On average, 10 million reads per sample were gener-
ated. The number of reads aligned to HBV genome (DQ089769.1) is 26935.5 in
median. Aligned reads were further processed for HBV-human junction identifi-
cation. Sequencing data is deposited in Sequence Read Archive (SRA) with ID
SRP062885. Refer to the Supplementary materials and methods for details.
Detection and experimental validation of A2S transcript
Multiple sequencing reads were found to align perfectly to a hypothesized HBV-
CCNA2 fusion transcript. The hypothesized transcript contains exon 2 of CCNA2, a
HBs gene fragment (282 nt. 458 nt.) and exon 3 of CCNA2. Since the partial HBs
gene insert of the hypothesized fusion transcript was only 177 bp long, library
design with 300 bp long insert size was able to span both chimeric junctions to
indicate they coexist on a single transcript. To validate the hypothesized A2S
transcript by PCR, primers were designed to flank exon 2 and exon 3 of CCNA2.
Sanger sequencing was performed on the PCR product to confirm its identity.Protein degradation assay
Determination of protein degradation was assayed as described previously. [32]
In brief, cells were transfected with flag- c-Myc-tagged WT CCNA2 and A2S con-
structs for 48 h and collected after treatment with cycloheximide (50 lg/ml) forJournal of Hepatology 2016the indicated time points. Cells were then lysed for Western blotting with anti-
flag or -c-Myc antibody. The band intensity of the Western blotting result was
measured by ImageJ. The protein abundance was then plotted against time. The
protein level of b-actin was used as an internal control.Results
Detection of HBV-human junction sites by transcriptome sequencing
Transcriptome sequencing was performed on 16 pairs of HBV-
associated HCCs and their corresponding NT-L tissues. HBV
sequences were detected in all patients, 13 of whom were
infected with HBV genotype C strain, while the others were with
genotype B strain (Supplementary Fig. 1). To detect transcripts
containing viral-human chimeric junctions, sequence reads were
aligned to human and HBV reference sequences and by GSNAP
through two alignment stages to maximize alignment sensitivity
and specificity. A total of 506 distinct HBV-human junctions were
detected; of these, 413 were found in the NT-L tissues, while 94
were found in the HCCs (Supplementary Table 2). However, the
average sequencing read depth covering the HBV-human junc-
tions was higher in HCCs (49.6) than in NT-Ls (25.4). This reduced
diversity of highly expressed HBV-human junctions in HCCs may
reflect the clonal origin of tumor cells, or positive selection of
tumor cells with growth-promoting HBV integration events.
To identify hotspots for HBV-human junctions, coordinates of
junctions on the viral arm were clustered in intervals of 50 nt. for
enrichment analysis. Of all the HBV-human junctions detected,
57% located on the HBx gene. Furthermore, the enrichment of chi-
meric junctions on HBx indicates preferential breaks of HBV at
the Direct Repeat 1 (DR1) site (1800 nt. 1850 nt.) upon integra-
tion (Fig. 1A).
Significant enrichment of HBV-human junctions at the human splice
sites
Our transcriptome sequencing results indicate additional peaks
(Fig. 1A) over HBV-human junctions, which were not observed
in previous whole-genome sequencing studies. To understand
the observation, we tested whether there was a significant differ-
ence in the proportion of junctions formed with the gene features
present on human transcribed region: exonic and splicing (Sup-
plementary Fig. 2). The results showed that HBV-human junc-
tions tended to form on human splice sites than on other
exonic regions remarkably. (p <2.2  1016, Z-test). Surprisingly,
we found that these junctions were recurrently formed in multi-
ple genes (CCNA2, TERT, NR3C2 and MLL4; Fig. 1C) and were most
frequently detected at 458 nt., followed by 282 nt. and 2449 nt.
on the HBV genome (in HBs and HBc genes) (Fig. 1B), suggesting
that these sites might be responsible for multiple splicing disrup-
tion events over different genes.
Identification of a novel HBV-CCNA2 chimeric transcript (A2S) in
HCC
Among the junctions found to be enriched on splice sites, two
HBV-human junctions (HBV 458 nt. and HBV 282 nt.) were most
common. These two junctions resulted in a novel chimeric tran-
script where human CCNA2 fused with a portion of the HBs gene
(282 to 458 nt.), as identified in sample 149T (Fig. 2) (Alignment
data shown in Supplementary Fig. 3). To validate this chimericvol. 64 j 1256–1264 1257
A120 (reads)
60
0
(nt.)
HBV-human junctions (Global) B
120 (reads)
60
0
(nt.)
HBV-human junctions (Splice site) 
Genes detected with HBV-human junction at human splice sitesC
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CCNA2 Cyclin A2 
282, 458 
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Intron 2 
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107T
NR3C2 Nuclear receptor subfamily 3, group C, member 2   458 Intron 2 308T
TERT Telomerase reverse transcriptase 458 Intron 2 383T
MLL4 Mixed-lineage leukemia 4 458 Intron 3 228T
Fig. 1. HBV-human chimeric junctions at splice sites. (A) Abundance of chimeric junctions on HBV genome. Note that the chimeric junctions were found more frequently
at site of 1800 nt. and 460 nt. of the HBV genome. (B) Chimeric junctions limited to human splice sites. Note that multiple peaks were found at 282 nt., 458 nt. and
2448 nt. The locations of HBV genes were annotated as S gene, polymerase gene, X gene, and pre-core gene, respectively. The blue bars indicate the number of reads
detected at the position. (C) List of genes detected with HBV-human junction at human splice sites. Only tumor-specific events are listed. (This figure appears in colour on
the web.)
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Fig. 2. Graphical illustration of CCNA2-HBs chimeric fusion transcript (A2S) sequence alignment. Reads alignment to the human CCNA2 and HBV are shown. Note that
HBs gene (282 nt. to 458 nt.) was integrated into intron 2 of CCNA2. Original data are shown in Supplementary Fig. 2.
Research Articletranscript (RNA), PCR amplification was performed on cDNA
using primers flanking HBs and CCNA2 (Supplementary Fig. 4A
and B), and two PCR products were detected. Sanger sequencing
performed on both PCR products confirmed that the HBs gene1258 Journal of Hepatology 2016from 282 nt. to 458 nt. was fused between the exon 2 and exon
3 of CCNA2 in the larger-sized product (Supplementary Fig. 4C).
This fusion of the HBs gene resulted in a novel HBV-CCNA2 chi-
meric transcript, which we named A2S.vol. 64 j 1256–1264
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Pre-mRNA splicing mechanism as a common mechanism in
generation of HBV-human chimera
To further examine whether A2S was generated at the genomic
or transcriptional level, genomic DNA of 149T was PCR-
amplified and Sanger-sequenced on CCNA2, with primers span-
ning exons 2 and 3. Two PCR products, approximately of
1500 bp (CCNA2 E2/E3 S) and 3000 bp (CCNA2 E2/E3 L), were
found (Supplementary Fig. 5A). The sequence of CCNA2E2/E3 S
was identical to the wild-type CCNA2, while that of CCNA2E2/
E3 L showed integration of a 1450 bp contiguous segment of
the HBV genome (3179–3215 nt. and 1–1412 nt.) into its intron
2 (Supplementary Fig. 5B). This confirmed the presence of HBV
integration into the CCNA2 gene.
Intriguingly, there was a large discrepancy between the inte-
grated HBV sequence (3179–3215 nt. and 1–1412 nt.) in the
genomic CCNA2 gene and that (282–458 nt.) in the CCNA2 tran-
script, with the insert in the transcript being only a small portion
of the insert in the gene (Fig. 3A and Supplementary Fig. 5B). This
difference between the genomic and transcriptional levels
strongly suggested that the A2S chimeric transcript was gener-
ated via a post-transcriptional pre-mRNA splicing mechanism
upon genomic integration.
Moreover, we observed that all splice donor and acceptor sites
of CCNA2 remained intact after the HBV integration. Under nor-
mal transcriptional splicing, the integrated HBV segment within
CCNA2 intron should have been removed. Therefore, the retention
of HBV 282–458 nt. in the A2S transcript required further expla-
nation. Inspection of the HBV sequence at 282–458 nt. revealed
the presence of a possible splice acceptor (AG) at 282 nt. and a
possible splice donor site (GT) at 458 nt. (Fig. 3B). These splice
acceptor and donor sites likely might have participated in the
alternative splicing event of CCNA2, leading to the retention of
the integrated HBV sequence from 282 nt. 458 nt. upon post-
transcriptional excision.
To further test the hypothesis on the formation of A2S through
pre-mRNA splicing of HBV and human genome, we ectopically
expressed a c-Myc-tagged construct of CCNA2 containing the
1450 bp contiguous segment of the HBV genome (3178–
3215 nt. and 1–1412 nt.) in intron 2 (HBVIn) in BEL-7402 HCC
cells (Supplementary Fig. 5C and D). Upon HBVIn ectopic expres-
sion, the protein and transcript produced had the same size with
those of A2S, indicating an occurrence of splicing event on the
pre-mRNA of HBVIn (Fig. 3C and D). This indicates that the
A2S chimeric protein was likely produced through post-
transcriptional pre-mRNA splicing between HBV and human
genome.
Prevalence of A2S chimeric transcript in human HCCs, the
corresponding non-tumorous livers, and non-HCC HBV-associated
cirrhotic livers
In the transcriptome sequencing, the A2S chimeric transcript was
found in the tumors in one of the 16 pairs of human HCCs. To fur-
ther study the prevalence of A2S chimeric transcript in HBV-
associated HCCs, the presence of A2S was examined in the cDNA
of a separate cohort of 32 pairs of HCCs and their corresponding
NT-Ls by PCR and Sanger sequencing. Two pairs of primers, 1)
HBVsF/R8 and 2) F2/HBVsR flanking different regions between
the HBs gene and CCNA2, were used for the PCR. As shown in
Fig. 4A, the A2S fusion transcript was found mainly in the HCCJournal of Hepatology 2016tumors. Sanger sequencing result of the 32 cases from the
expanded cohort further confirmed the presence of the A2S chi-
meric transcript in 4 more tumors (247T, 346T, 284T and
340T). In another case (343NT), A2S was found in the NT-L tissue
only and not in the HCC tumor (Fig. 4B). Altogether, A2S was
found in 5 (10.4%) of the 48 HCC tumors (16 from transcriptome
sequencing and 32 from the expanded cohort) (Fig. 4C). In addi-
tion, the presence of A2S chimeric transcripts was also examined
in 22 cases of non-HCC HBV-associated cirrhotic livers (Supple-
mentary Fig. 6) and the results showed no A2S transcript was
found in all of these cases. These results indicate that A2S was
preferentially found in the HCC tumors and raised the question
of its potential tumorigenicity. Interestingly, all 6 HBV-CCNA2
fusion transcripts have identical HBs sequence fragment inserted
between exon 2 and exon 3 of CCNA2 transcript, supporting our
hypothesis of pre-mRNA splicing mechanism in the generation
of HBV-human chimeric transcript. Other than the transcript,
the encoded A2S protein was also found to be expressed in
149T tumor, 247T tumor and 346T tumor liver (Supplementary
Fig. 7). This agreed with the occurrence of A2S at the transcript
level. This confirmed the plausibility in the generation of the
A2S chimeric protein.Induction of cell cycle progression by A2S chimeric protein, with
same effect as wild-type CCNA2 overexpression
CCNA2 is a member of the cyclin family, which regulates cell
cycle progression in somatic cells. It is important in the initiation
and progression of S phase and necessary for G2-M exit and tran-
sition [10,11]. Taken into account the function of CCNA2 acting as
a cell cycle regulator, we postulated that alteration of the CCNA2
activity in proper cell cycle upon HBV integration might result in
neoplastic transformation.
To assess this hypothesis, the cell cycle patterns were ana-
lyzed by flow cytometry in BEL-7402 and SMMC-7721 HCC cells.
We ectopically expressed IRES-EGFP-tagged A2S and wild-type
CCNA2 in these cells and only the EGFP-positive cells, i.e.
CCNA2- or A2S-overexpressing cells, were analyzed. In
Fig. 5A and B, both A2S and wild-type CCNA2 transfectants
demonstrated enhanced S phase progression with increased per-
centages of cells in S and G2-M phases, as compared with the
empty vector control. Both CCNA2 and A2S BEL7402 stable trans-
fectants (Supplementary Fig. 8A) also showed a significantly
stronger Bromodeoxyuridine (BrdU) staining indicating higher
DNA synthesis rate in BrdU cell proliferation assay, increased
numbers of colonies formed in colony formation and soft agar
colony formation assays, when compared to the empty vector
control (Supplementary Fig. 8B, C and D). In addition, the
enhanced cell growth ability by CCNA2 and A2S was further evi-
denced in an immortalized normal liver cell line LO2. CCNA2 and
A2S LO2 transfectants showed a higher proliferation rate in cell
proliferation assay (Supplementary Fig. 9A), a stronger BrdU
staining in BrdU proliferation assay (Supplementary Fig. 9B), an
induction of S phase progression in flow cytometry (Supplemen-
tary Fig. 9C), and an increased number of colonies formed in col-
ony formation assay (Supplementary Fig. 9D). These results
showed that the A2S fusion protein retained the ability of wild-
type CCNA2 in enhancing cell proliferation and, notably, this abil-
ity was comparable to that of the overexpression of wild-type
CCNA2.vol. 64 j 1256–1264 1259
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Research ArticleDisruption of proper degradation upon partial HBs fusion in A2S
chimeric protein
A proper CCNA2 degradation is required for a rigid cell cycle pro-
gression. CCNA2 starts to accumulate during the S phase and is
abruptly destroyed before the metaphase by ubiquitin-
mediated proteolysis [12]. Therefore, we first investigated the
influence of HBs gene fusion on the change of structural domains
by protein structure prediction. Although the insertion of partial
HBs protein did not directly disrupt the functional motifs e.g.
cyclin box or D-box motif in CCNA2 (Supplementary Fig. 10),
the analysis illustrated more frequent formation of a-helix1260 Journal of Hepatology 2016subunits upon partial S protein fusion in the A2S chimeric protein
(Fig. 6A). Moreover, the new a-helix subunits mainly located near
the N-terminus (1 aa to 235 aa) of A2S and disrupted the original
conformation of destruction box (D-Box) motif (47 aa to 57 aa) of
CCNA2. An intact D-box motif is responsible for the destruction of
cyclins by programmed proteolysis at the end of mitosis to exert
cell cycle control [13,14]. Therefore, we hypothesized that the
A2S protein was rendered a non-degradable property upon the
HBs fusion event.
Consistent with this hypothesis, the degradation rate of A2S
protein was slower than that of the wild-type CCNA2 protein,
as shown in BEL7402 expressing flag-tagged A2S and wild-typevol. 64 j 1256–1264
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Fig. 5. A2S exerted a similar effect on cell cycle progression as wild-type
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JOURNAL OF HEPATOLOGYCCNA2 (Fig. 6B). In BEL7402 cells, the levels of A2S protein at 1, 2
and 3 h were similar to that at 0 h after supplementation of cyclo-
heximide (CHX), while more than 50% of wild-type CCNA2 pro-
tein was degraded at the first hour. These results were further
confirmed in the immortalized liver cell line LO2 (Fig. 6C). The
result provided us with the first hint on how partial HBs gene
(282 nt. to 458 nt.) fusion affected the degradation profile of
A2S chimeric protein.Journal of Hepatology 2016Discussion
In this study, we identified a novel mechanism underlying the
formation of HBV-human chimeric transcripts from intronic-
integrated HBV genome, exemplified by the recurrent HBV-
CCNA2 fusion transcript A2S. We uniquely demonstrated that
the A2S was produced by a novel pre-mRNA splicing of the host
genome after HBV integration at the intron 2 of CCNA2 gene, with
subsequent formation of a 177 bp in-frame pseudo-exon and the
fusion transcript A2S acquired potential oncogenic properties.
HBV integration into human genome is a major causative fac-
tor for hepatocarcinogenesis. A number of recent next generationvol. 64 j 1256–1264 1261
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indicates difference on a-helix structure between the CCNA2 and A2S. (B & C) The BEL7402 and LO2 cells were transiently transfected with flag-tagged CCNA2 or A2S
constructs. 48 h after transfection, 50 lg/ml cyclohexamide was added and the cells were harvested at indicated time points. Western blot analysis was performed using
flag antibody and b-actin was used as internal control. The protein level of CCNA2 was decreased while that of A2S was unchanged in BEL7402 and LO2 cells. The
degradation chart of CCNA2 and A2S. The band intensity of the Western blotting was measured by ImageJ and the optical intensity plotted against time. Note that the
protein level of AS2 in the transfected cells was unchanged in the degradation chart. (This figure appears in colour on the web.)
Research Articlesequencing studies have highlighted recurrent regions of HBV
integration [9,15]. In a very recent whole-transcriptome sequenc-
ing study characterizing transcribed HBV-human fusions,
although HBV-human chimeric transcripts were widely studied,
only HBV-positive HCC cell lines were investigated for viral inte-
grants, thus with restriction at in vitro level [16]. In our present
study, we employed transcriptome sequencing and functional
assays in an attempt to examine the impact of post-
transcriptional modification on HBV integration in vivo and its
chimera derivatives in paired human HCCs and their NT-Ls. In
accord with the previous studies [17–19], recurrent HBV integra-
tion was also detected in CCNA2, TERT andMLL4 genes in our find-
ings (Fig. 1C). Beyond these findings, this present study has
provided the first evidence detailing the significant enrichment
of HBV-human junction hotspots confined to splice sites (exon
boundaries) of the host arm. For the same set of junctions over
the viral arm, enrichments were observed on three junctions
located at 282 nt., 458 nt. and 2449 nt., instead of the major
DR1 breakpoint at 1824 nt., and observed in a global manner.
Moreover, we have revealed a common but novel pre-mRNA
splicing mechanism of HBV intronic integration, generating
potential oncogenic HBV-human chimeras in HCC.
In the present study, more HBV-human junctions were found
in NT-Ls (413 of 507, about 81%) than in T-L tissues (94 of 507,1262 Journal of Hepatology 2016about 19%), which is in agreement with previous reports
[20,15]. However, our observation was different from a recent
HBV integration study using whole-genome deep sequencing
[21] and study of Sung et al. [9], which showed that the number
of HBV integration sites was higher in tumor derived tissues than
that in NT livers. This may be due to the technical differences
between transcriptome sequencing and that of whole-genome
sequencing employed by other HBV integration studies. The
higher expression of cis/trans-activated chimeric transcripts pre-
sent in the HBV integrated hepatocytes has enabled detection by
transcriptome sequencing. Furthermore, a previous study also
provided an explanation for similar observations [4] where viral
integration is shown to occur during HBV chronic infection before
HCC initiation. Hepatocytes with viral integration expanded dur-
ing chronic hepatitis and some cells took part in the formation of
focal proliferative lesions and gained growth advantages, there-
fore, leading to clonal expansions during tumorigenesis. This
echoed with our observation that the average sequencing read
depth covering the HBV-human junctions was higher in HCCs
(49.6) than in NT-Ls (25.4) as a result of clonal expansion.
By confining our search of HBV-human chimeric junctions to
human splice sites, we showed that in CCNA2, the foreign splicing
events at two HBV sites (282 nt. and 458 nt.) were capable of
introducing an insert without frame-shift between the exon 2vol. 64 j 1256–1264
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and exon 3. Of interest, our study showed insertion of new splice
acceptor (AG) from HBV 282 nt. and splice donor (GT) from HBV
458 nt. in the integrated fragment of HBs into the CCNA2 gene,
and GT-AG splice pair is a canonical splice site previously
reported in mammalian genomes [22]. In spite of the randomness
of HBV integration into human genomic DNA, it is worth noting
that as long as the inserted viral sequence contains the two
HBV foreign splice sites, this post-transcriptional pre-mRNA
splicing mechanism allows the integrated HBV sequence to gen-
erate an identical fusion transcript regardless of the precise
breakpoints of both the human and HBV genomes. In fact, splic-
ing events have been widely reported in HBV genome [23,24],
and are involved in the post-transcriptonal control of HBV gene
expression [25] and generation of truncated HBV protein [24].
However, the role of pre-mRNA splicing in generating HBV-
human chimeric protein was not previously appreciated. Also,
there have been limited reports on the link between intronic
HBV integration and HCC development. Previous findings have
mostly focused on integrations in host exonic and promoter
regions, which are believed to exert a greater influence on protein
function and transcriptional regulation [9,15]. As a result, the
impact of intronic integration on coding transcripts has been
underestimated. Given the total intronic region is more than
ten times longer than the exonic regions, our study has greatly
highlighted the significance of HBV intronic integration by show-
ing intronic integrations could alter the sequence of protein cod-
ing genes and probably the protein conformation, which greatly
enhances the capability of HBV in affecting human protein
functions.
As far as we understand, this is the first report of the identifi-
cation of this novel chimera A2S. CCNA2 is a cell cycle regulatory
protein which acts as a regulatory subunit of CDKs. Genomic inte-
gration events were recurrently found within intron 2 of CCNA2
in previous studies [15]. Early in 1990, Wang et al. first reported
the existence of an HBV-fused CCNA2 in HBV-associated HCC
[17,26]. Later, the oncogenic property of the HBV-altered CCNA2,
in which N-terminal part was replaced by the HBV envelope pro-
tein, was further demonstrated by Berasain et al. They showed
that rat kidney cell was transformed by the disrupted CCNA2
due to abnormal cellular localization of the protein [27]. These
studies have provided evidence that HBV promotes cellular trans-
formation through integration into CCNA2 gene. However, the
underlying mechanism of the generation of chimeric protein
and the viral-induced carcinogenetic changes were not fully
explained in these studies.
In our study, the splicing events introduced by the two splice
sites, 282 nt. and 458 nt., were more commonly found in HCC
tumors, indicating the splicing events induced by the two splice
site hotspots may be implicated in hepatocarcinogenesis by alter-
ing the functions of different genes upon HBV fusion. Other than
CCNA2, the chimeric transcripts listed in Fig. 1C may also lead to
the production of HBV-human chimeric proteins. In NR3C2 and
TERT, HBV was found to form chimera from intron 2 and spliced
with exon 3 at HBV 458 nt. However, for NR3C2, the transcription
was not in-frame as indicated in the Supplementary Fig. 11A, and
acquired a stop codon in exon 3. Therefore, in this splicing event,
we may speculate that a truncated HBV-NR3C2 chimeric protein
may be produce. For TERT, the transcription was in-frame (Sup-
plementary Fig. 11B), and the chimeric transcript could encode
a functional chimeric protein. It is also speculated that the active
transcription by the fused HBV-S promoter together with theJournal of Hepatology 2016cryptic splicing could cis-activate TERT. Possible functional
impact of the HBs-TERT and HBV-NR3C2 chimeras requires fur-
ther investigation.
HBV integration into the intron 2 of CCNA2 followed by pre-
mRNA splicing was capable of producing a HBV-human fusion
product A2S, which may provide a selective advantage in tumori-
genesis. In our cohort, we detected recurrent A2S expression in 6
of 48 (12.5%) of the HBV-associated HCCs, of which more than
80% (5 of 6) was found in the tumors only, implicating its poten-
tial tumorigenicity. Moreover, it was interesting to find no A2S
transcript in the 22 cases of HBV-associated non-HCC cirrhotic
livers in this study (Supplementary Fig. 6). This suggests that this
event is possibly in close relation with the onset of HCC. In addi-
tion, it is noteworthy that the ability of induction of S phase pro-
gression of A2S was comparable to overexpression of the wild-
type CCNA2. Since upregulation of CCNA2 is highly associated
with tumorigenesis in a number of cancers including HCC
[12,28,29], dysregulation of CCNA2 may play a direct role in cel-
lular transformation and oncogenesis through the loss of cell
cycle control [30]. This result suggests a potential oncogenic role
of A2S in hepatocarcinogenesis and more functional analysis
should be performed to confirm the tumorigenicity in future
studies. Taken together, our findings have emphasized the impor-
tance of the A2S chimeric protein in conferring oncogenic advan-
tages in the progression of HCC.
In cyclin degradation, the destruction box in the N-terminus
binds with a series of proteins and produces a hybrid that is sus-
ceptible to proteolysis through ubiquitin pathway [14]. In line
with the findings on potential tumorigenicity of the A2S chimeric
protein, we also demonstrated that the A2S protein acquired an
altered regulatory cascade when compared to the wild-type
CCNA2. In the A2S chimeric protein, the C-terminus functional
motifs including the cyclin box motifs, which play a key role in
cell cycle regulation [12,31], were undisrupted upon HBV fusion.
However, the proper degradation of the protein was hindered by
an indirect disruption on the conformation of destruction box
located on the N-terminus of CCNA2. As demonstrated, A2S
fusion protein was still capable of progressing cell cycle in the
S phase. This functional characteristic was distinct from the other
previously reported HBV-CCNA2 chimeric protein, in which the
N-terminal part was replaced by the HBV envelope protein [17],
the destruction box of the protein was directly replaced by HBs
protein and its oncogenicity was associated with an abnormal
cellular localization in the endoplasmic reticulum membrane
instead of cell cycle deregulation. In the present study, together
with the finding that A2S chimeric protein had a positive influ-
ence in S phase progression, the inability of degradation of A2S
protein was likely to ultimately increase the overall expression
of A2S protein along the cell cycle progression. We speculated
that the accumulation of non-degradable A2S not only favored
the progression of S phase in enhancing cell proliferation, but
might also disturb the proper mitotic exit in the progression of
G2-M phase. A delay of mitotic exit might result in abnormal
chromosome segregation and hence chromosomal instability
promoting cancer susceptibility.
In summary, this study has highlighted the importance of HBV
involvement in the mammalian pre-mRNA splicing machinery, a
previously omitted but important mechanism, in the generation
of potential tumorigenic HBV-human chimeras. Our study has
also identified a novel potential tumorigenic HBV-human chi-
mera A2S, and provided insight on the impact of intronic HBVvol. 64 j 1256–1264 1263
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integration with the gain of splice sites in the development of
HBV-associated HCC.Financial support
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